 |
|
Effect of a Treatment Strategy Consisting of Pravastatin, Vitamin E, and Homocysteine Lowering on Carotid Intima-Media Thickness, Endothelial Function, and Renal Function in Patients With Mild to Moderate Chronic Kidney Disease Results From the Anti-Oxidant Therapy in Chronic Renal Insufficiency (ATIC) Study
Prabath W. B. Nanayakkara, MD;
Coen van Guldener, MD;
Piet M. ter Wee, MD, PhD;
Peter G. Scheffer, MD, PhD;
Frans J. van Ittersum, MD, PhD;
Jos W. Twisk, MD, PhD;
Tom Teerlink, MD;
Wim van Dorp, MD;
Coen D. A. Stehouwer, MD
Arch Intern Med. 2007;167(12):1262-1270.
ABSTRACT
| |
Background Patients with chronic kidney disease have an increased risk of cardiovascular disease. Oxidative stress has been proposed to play a role in the development of cardiovascular disease among these patients.
Methods We conducted a randomized, double-blind trial in 93 patients (Cockcroft-Gault equation: creatinine clearance, 38 ± 15 [mean ± SD] mL/min per 1.73 m2 [0.63 ± 0.25 mL/s per m2]) to investigate the effect of a treatment strategy designed primarily to achieve stepwise oxidative stress reduction on common carotid intima-media thickness (CC-IMT), brachial artery flow-mediated dilatation (BA-FMD), albuminuria, and renal function. The treatment group received a regimen of pravastatin to which vitamin E supplementation was added after 6 months and homocysteine-lowering therapy after another 6 months. Blood pressure in both groups was managed according to a standard protocol. The placebo group received matching placebos. Measurement of CC-IMT and BA-FMD was performed at randomization after 6, 12, and 18 months. Patients were followed up for 2 years. Generalized estimating equations were used for analysis.
Results Compared with placebo, active treatment was associated with a decrease in CC-IMT (after 18 months: from 0.68 to 0.63 mm in the treatment group and from 0.65 to 0.71 mm in the placebo group; P<.001), an increase in BA-FMD (after 18 months: from 4.66% to 7.56% in the treatment group and from 6.21% to 4.73% in the placebo group; P<.001), and an attenuated increase in urinary albumin excretion over time (P = .04 for between-group difference after 24 months), but no effect was observed on renal function.
Conclusion In patients with mild to moderate chronic kidney disease, 18 months of a treatment strategy along with well-controlled blood pressure reduced CC-IMT and urinary albumin excretion and increased BA-FMD.
Trial Registration clinicaltrials.gov Identifier: NCT00384618
INTRODUCTION
Patients with mild to moderate chronic kidney disease (CKD) have an increased risk of cardiovascular disease,1-6 which cannot fully be explained by the presence of known cardiovascular risk factors such as hypertension, diabetes, smoking, and dyslipidemia.3, 7-9 Therefore, other atherothrombotic mechanisms play a role.8-9 In the last few years, compelling evidence has emerged pointing to the contributing role of oxidative stress in the pathogenesis of cardiovascular complications in CKD.10-11 Oxidative stress in patients with CKD has been attributed to the effects of uremic toxins, angiotensin II, proinflammatory cytokines, and hyperhomocysteinemia.12-13
Statins have been shown to reduce oxidative stress in hypercholesterolemic patients.14-15 Vitamin E supplementation and homocysteine-lowering therapy have also been shown to reduce oxidative stress in several patient populations.10, 16-17 However, in dialysis patients, studies aimed at reducing cardiovascular events with statins18 and homocysteine-lowering therapy19 have not shown positive results. A possible explanation for these disappointing findings is that patients at the start of dialysis often have advanced cardiovascular disease,2 which may be difficult to reverse in this phase. However, only a few cardiovascular intervention studies have been performed on patients with mild to moderate CKD,20 and most of the large intervention trials with statins have excluded patients with moderate renal failure.
In view of these considerations, we designed the Anti-Oxidant Therapy in Chronic Renal Insufficiency (ATIC) Study to examine the effect of a treatment strategy primarily designed to achieve a stepwise reduction of oxidative stress in a population of patients with mild to moderate CKD21 and well-controlled blood pressure. The treatment strategy consisted of pravastatin, vitamin E, and homocysteine-lowering therapy on common carotid intima-media thickness (CC-IMT) (a strong surrogate marker of cardiovascular risk in the general22 and the dialysis23 populations), brachial artery flow-mediated dilatation (BA-FMD) (a marker of endothelial function that can be impaired by increased oxidative stress24-25), estimated glomerular filtration rate (eGFR), and urinary albumin excretion. Plasma-oxidized low-density lipoprotein (oxLDL)26 and malondialdehyde27 were measured as oxidative stress parameters. Interventions were added to the regimen every 6 months to investigate both the effects of individual interventions and the effects of the entire strategy on the end points.
METHODS
PATIENTS
Between May 2001 and December 2002, patients with a creatinine clearance of 15 to 70 mL/min per 1.73 m2 (0.25-1.17 mL/s per m2) (according to the Cockcroft-Gault equation) from 7 outpatient clinics in Amsterdam, the Netherlands, were screened for eligibility for participation in the ATIC Study, a randomized, double-blind, placebo-controlled trial investigating the effects of oxidative stress–lowering treatment on vascular structure and function in nondiabetic patients with chronic renal failure who had no manifest arterial occlusive disease.
DESIGN
Participants were randomized after stratification for prior use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, creatinine clearance (between 15-39 and 40-70 mL/min per 1.73 m2 [between 0.25-0.65 and 0.66-1.17 mL/s per m2]), and age (between 20-49 and 50-80 years). Randomization was carried out centrally by means of a computer-generated sequence involving randomized blocks of 4, and concealed envelopes were kept by 1 hospital pharmacist. Unblinding was performed after the data analysis. After randomization, participants in the treatment group were treated with pravastatin (40 mg/d), vitamin E ( -tocopherol acetate) (300 mg/d) was added to the regimen 6 months later, and homocysteine-lowering therapy (folic acid [5 mg/d], pyridoxine hydrochloride [100 mg/d], and cyanacobalamin [1 mg/d] in 1 tablet) was added 6 months after that. Patients continued this triple therapy for another 12 months (Figure 1). Patients in the placebo group received matching placebos at the onset and 6 and 12 months later. Adherence to therapy was assessed by counting leftover pills. Subjects who were not using angiotensin-converting enzyme inhibitors or angiotensin receptor blockers at inclusion received an angiotensin-converting enzyme inhibitor (fosinopril [10 mg/d]) for at least 2 weeks before the baseline measurements and randomization. Those who were taking angiotensin receptor blockers continued taking them. During the following visits, blood pressure was controlled according to a standard protocol in which hydrochlorothiazide (a loop diuretic was administered if the eGFR was <30 mL/min), metoprolol succinate, amlodipine mesilate, or doxazosin were added in that order to achieve a blood pressure of less than 140/90 mm Hg. Measurement of the CC-IMT and BA-FMD and laboratory tests were performed in all cases at randomization and at 6, 12, and 18 months after randomization. Laboratory tests were also performed after 24 months. We excluded individuals with diabetes mellitus (American Diabetes Association criteria), active vasculitis, nephrotic syndrome, renal transplantation, a fasting total cholesterol level higher than 270 mg/dL (7.00 mmol/L), cholesterol-lowering therapy within 3 months prior to inclusion, or ischemic coronary, cerebrovascular, or peripheral arterial disease. Ninety-three patients (out of 118 eligible patients) took part in the study (Figure 1). Written informed consent was obtained from all participants, and the study was approved by the ethical committees at each center.
|
|
|
|
Figure 1. Flow of participants through each stage of the study.
|
|
|
PROCEDURES
Patients were examined in fasting state in a temperature-controlled (25°C) room. Data were collected with regard to age, medications, and smoking status (having smoked in the past year), and a history was obtained to exclude peripheral, cerebral, and coronary vascular disease. After 30 minutes of rest, blood pressure was measured with an oscillometric device (Press-Mate BP-8800; Colin Co, Komaki City, Japan) and expressed as the mean value of 6 measurements over a period of 30 minutes. Blood samples were collected after 15 minutes of rest and immediately placed on ice; they were centrifuged within 15 minutes and stored at –80°C until analysis.
CAROTID ARTERY ULTRASONOGRAPHY
The CC-IMT measurements were performed using a medical scanner (Scanner 350; Pie Medical, Maastricht, the Netherlands) with a linear array transducer of 7.5 MHz attached to a data registration and processing unit (Wall Track System II; Pie Medical) as described in detail elsewhere.28-29
BRACHIAL ARTERY ULTRASONOGRAPHY
The measurement protocol for BA-FMD has also been described in detail elsewhere.30-31 Briefly, baseline diameter (mean of 3 measurements) and peak flow velocity (mean of 2 measurements) were determined. A pressure cuff, placed on the forearm, was then inflated and kept constant at suprasystolic pressure. After 5 minutes, the cuff was released to increase blood flow. After cuff release, maximum peak flow velocity was measured within 15 seconds and diameter was measured at 45, 90, 120, 150, and 300 seconds. The BA-FMD was calculated as the percentage of change in the maximum postocclusion diameter of the brachial artery relative to the mean baseline diameter.
REPRODUCIBILITY
All ultrasound measurements at each visit were performed by a single observer who was blinded to the treatment allocation. Reproducibility was assessed in 10 healthy subjects (43 ± 13 [mean ± SD] years) who were examined by the same observer twice, 3 weeks apart. The intraobserver coefficient of variation (CV) (SD of the mean difference/[2 x pooled mean] ) was 10% for the CC-IMT measurement and 15% for the BA-FMD measurement.
LABORATORY ANALYSES
Serum creatinine concentration was assessed by a kinetic Jaffé method. Plasma total (free plus protein-bound) homocysteine was measured with an automated fluorescence polarization immunoassay analyzer (IMx; Abbott Laboratories, Abbott Park, Ill), with an interassay CV of less than 4%.32 Renal function was estimated by the Modification of Diet in Renal Disease (MDRD) study equation (eGFR in milliliters per minute per 1.73 m2, per Levey equation 7)33 and by the Cockcroft-Gault and Dubois formulas (creatinine clearance in milliliters per minute per 1.73 m2).34-35
Urinary albumin was measured in a 24-hour urine collection at each visit and analyzed using a microalbumin antiserum analyzer (Beckman Array 360 Analyzer; Global Medical Instrumentation Inc, Clearwater, Minn). The CV for the between-run imprecision was 5.0% at a mean concentration of 11.4 mg/L and 5.0% at a mean concentration of 72.6 mg/L.
The plasma concentration of oxLDL was measured by a competitive enzyme-linked immunosorbent assay (Mercodia, Uppsala, Sweden).36 The intra-assay and interassay CVs were 4.8% and 7.8%, respectively. Malondialdehyde in EDTA plasma was determined after reaction with thiobarbituric acid, with an added alkaline hydrolysis step as described elsewhere.37 The within-run and between-run variation was 3.5% and 8.7%, respectively.
POWER CALCULATION
The number of patients needed to detect an absolute CC-IMT difference of 0.09 mm between the groups over 18 months with 3 longitudinal measurements with a power of 90%, an value of 0.05, and an SD of 0.13 was 38 patients per group. Taking into account a dropout percentage of 20%, the number needed per group was 47 patients.
STATISTICAL ANALYSES
Statistical analysis was performed with Stata 7.0 (Stata Corp, College Station, Tex). All analyses were performed according to the intention-to-treat principle. Outcome variables were analyzed with generalized estimating equations, an established longitudinal data analysis technique.38 In the primary generalized estimating equations model, the outcome variable studied (eg, CC-IMT or BA-FMD) was analyzed as a dependent variable using treatment strategy (1, intervention group; 0, placebo group) as a key independent variable adjusted for time and, if appropriate, for previous observations using extra independent variables. Also, to evaluate effect modification, the product term of group and time (group x time) was added as an independent variable. In case of skewed data, analyses were performed after log transformation.
Data are presented in graphs indicating means with standard errors. All these variables except urinary albumin were normally distributed. P<.05 was considered statistically significant.
RESULTS
Table 1 shows the baseline characteristics of the participants. Of 93 patients who were included in the study, 6 withdrew after undergoing the baseline measurement and 87 underwent the second measurement and were included in the final analysis (Figure 1). After 2 years, 72 patients in the treatment group and 77 patients in the placebo group were still taking the drugs. Compliance at each follow-up visit was defined as consumption of at least 80% of the scheduled tablets since the previous visit. Four patients in the treatment group and 2 patients in the placebo group consumed more than 60% but less than 80% of the allocated tablets during the study period; all other participants took at least 80% of their scheduled tablets.
|
|
|
|
Table 1. Baseline Characteristics of the Participants*
|
|
|
COMMON CAROTID INTIMA-MEDIA THICKNESS
After 18 months, the mean CC-IMT had decreased from 0.68 to 0.63 mm in the treatment group, whereas it had increased from 0.65 to 0.71 mm in the placebo group (P<.001 for between-group difference) (Figure 2). After adjustment for baseline values of CC-IMT, the treatment strategy was associated with a CC-IMT lowering of 0.13 mm (95% confidence interval [CI], 0.10-0.16 mm) at 18 months. The largest change in CC-IMT (from 0.68 to 0.65 mm in the treatment group; P<.001 for between-group difference after 6 months) was seen in the first 6 months of therapy. After adjustment for baseline values of CC-IMT, the treatment strategy was associated with a CC-IMT lowering of 0.07 mm (95% CI, 0.05-0.09 mm) after 6 months.
|
|
|
|
Figure 2. Change in mean (SE) common carotid intima-media thickness (CC-IMT), with the P values for between-group differences. For 0 to 6 months, 6 to 12 months, 12 to 18 months, and 0 to 18 months, P<.001. Error bars indicate SE.
|
|
|
BRACHIAL ARTERY FLOW-MEDIATED DILATATION
After 18 months, the BA-FMD had increased from 4.66% to 7.56% in the treatment group, whereas it had decreased from 6.21% to 4.73% in the placebo group (P<.001 for between-group difference after 18 months) (Figure 3). After adjustment for baseline values of BA-FMD and time, the treatment strategy was associated with a BA-FMD increase of 3.18% (95% CI, 1.23%-5.13%) after 18 months. After 6 months, the BA-FMD had increased from 4.66% to 6.73% in the treatment group and from 6.21% to 6.43% in the placebo group (P = .11 for between-group difference after 6 months) (Figure 3).
|
|
|
|
Figure 3. Change in mean ( SE) brachial artery flow-mediated vasodilatation (BA-FMD), with the P values for between-group differences. For 0 to 6 months, P = 11; for 6 to 12 months, P = .009; and for 12 to 18 months and 0 to 18 months, P = .001. Error bars indicate SE.
|
|
|
RENAL FUNCTION
After 24 months, the mean eGFR (MDRD formula) had decreased from 35 to 33 mL/min per 1.73 m2 (from 0.58 to 0.55 mL/s per m2) in the placebo group and increased from 32 to 35 mL/min per 1.73 m2 (from 0.53 to 0.58 mL/s per m2) in the treatment group (P = .89 for between-group difference) (Figure 4). After adjustment for baseline values and time, the treatment strategy was associated with a 0.10 mL/min per 1.73 m2 (0.002 mL/s per m2) (95% CI, –2.11 to 1.92 mL/min per 1.73 m2 [95% CI, –0.035 to 0.032 mL/s per m2]) MDRD decrease at 18 months and a 0.06 mL/min per 1.73 m2 (0.001 mL/s per m2) (95% CI, –2.55 to 2.66 mL/min per 1.73 m2 [95% CI, –0.042 to 0.044 mL/s per m2]) MDRD increase at 24 months.
|
|
|
|
Figure 4. Change in mean (SE) estimated glomerular filtration rate (eGFR) based on the Modification of Diet in Renal Disease formula (milliliters per minutes per 173 m2, per Levey equation 7), with the P values for between-group differences. For 0 to 6 months, P = .79; for 6 to 12 months, P = .60; for 12 to 18 months, P = .21; for 18 to 24 months, P = .39; and for 0 to 24 months, P = .33. Error bars indicate SE.
|
|
|
URINARY ALBUMIN EXCRETION
After 24 months, the median urinary albumin excretion had changed from 71 mg/24 h (range, 3-2601 mg/24 h) to 107 mg/24 h (range, 5-3545 mg/24 h) in the placebo group and from 45 mg/24 h (range, 3-3420 mg/24 h) to 77 mg/24 h (3-2509 mg/24 h) in the treatment group. After adjustment for baseline values and time, the treatment strategy was associated with a 34% (95% CI, 3%-44%; P = .04) reduction of urinary albumin excretion compared with the placebo group after 24 months (Figure 5). After 6 months, the median urinary albumin excretion had changed from 71 mg/24 h (range, 3-2601 mg/24 h) to 94 mg/24 h (range, 1.6-3927 mg/24 h) in the placebo group and from 45 mg/24 h (range, 3-3420 mg/24 h) to 87 mg/24 h (range, 6-2521 mg/24 h) in the treatment group.
|
|
|
|
Figure 5. Change in mean (SE) log-transformed urinary albumin excretion, with the P values for between-group differences. For 0 to 6 months, P = .03; for 6 to 12 months, P = .02; for 12 to 18 months, P = .03; for 18 to 24 months, P = .06; and for 0 to 24 months, P = .04. Error bars indicate SE.
|
|
|
After adjustment for baseline values and time, the treatment strategy was associated with a 20% (95% CI, 10%-33%; P = .02) reduction of urinary albumin excretion compared with the placebo group at 6 months. Additional analyses showed a 19% (95% CI, 5%-30%; P = .008) reduction in urinary albumin excretion in the treatment group in the 50 patients with urinary albumin excretion of more than 30 mg/24 h at baseline, but no effect in the 30 patients with urinary albumin excretion of less than 30 mg/24 h at baseline.
BLOOD PRESSURE
After 24 months, the mean ± SD systolic blood pressure was 134 ± 27 mm Hg in the treatment group and 134 ± 22 mm Hg in the placebo group (P = .14 for between-group difference). There was no statistically significant difference in the systolic blood pressure at any point during the study (Figure 6). After 24 months, the mean diastolic blood pressure was 80 ± 12 mm Hg in the treatment group and 76 ± 11 mm Hg in the placebo group (P = .06 for between-group difference). Adjustment for systolic, diastolic, or mean blood pressure difference at any point in the analyses of CC-IMT, BA-FMD, or urinary albumin excretion did not alter the above-mentioned results.
|
|
|
|
Figure 6. Change in mean (SE) blood pressure, with the P values for between-group differences. Error bars indicate SE.
|
|
|
After 24 months, there was a strong and significant reduction of oxLDL (P<.001) and low-density lipoprotein cholesterol (P<.001) levels with the treatment strategy (Table 2). There was no significant reduction of plasma malondialdehyde (P = .13) during the study period (Table 2). There were 19 dropouts (11 from the treatment group and 8 from the placebo group) and 6 cardiovascular events during the study (Table 3).
|
|
|
|
Table 2. Changes in Oxidized Low-Density Lipoprotein (LDL) Cholesterol and Plasma Malondialdehyde, LDL Cholesterol, High-Density Lipoprotein (HDL) Cholesterol, Triglyceride, and Homocysteine Levels During the Study*
|
|
|
|
|
|
|
Table 3. Clinical Cardiovascular Events and Adverse Events and Withdrawals in Both Groups During the Study
|
|
|
COMMENT
The main finding of this study is that, in patients with mild to moderate nondiabetic CKD who had no manifest arterial occlusive disease and had well-controlled blood pressure, 18 months of treatment with an oxidative stress–lowering strategy consisting of pravastatin, vitamin E, and homocysteine-lowering therapy resulted in a statistically significant reduction in CC-IMT (P<.001) and a statistically significant improvement in BA-FMD (P = .001). There was no statistically significant effect on eGFR (P = .89). However, treatment was associated with an attenuated increase in urinary albumin excretion over time.
Cardiovascular morbidity and mortality are extremely high in patients with end-stage renal disease,1-2 and the results of intervention studies aimed at the reduction of cardiovascular events with statins18 and homocysteine-lowering therapy19 in these patients have been disappointing. These results may suggest that the extent and nature of vascular disease in patients with end-stage renal disease makes such treatment options less effective than in other patient groups. Therefore, we evaluated whether intervention at an earlier stage of CKD (Kidney Disease Outcomes Quality Initiative [K/DOQI] stages 2 through 421) would have beneficial effects on 3 strong surrogate estimates of cardiovascular outcome,22, 25, 39 ie, CC-IMT, BA-FMD, and urinary albumin excretion. Furthermore, and in contrast with most other lipid trials,40-42 the design of our study included formal control of blood pressure (<140/90 mm Hg) using a strict protocol. Blood pressure control is extremely important, as hypertension is very frequent in patients with CKD, and adequate blood pressure control in patients with mild to moderate renal disease slows the decline of the eGFR and decreases cardiovascular morbidity and mortality.43 Renin-angiotensin system blockade, in particular, has been shown to reduce proteinuria and to retard the progression of CKD, in part independent of blood pressure lowering.43 Therefore, the results of the present study should be interpreted as the effect of the treatment strategy in conjunction with well-controlled blood pressure.
Very few data are available on the effects of statins on cardiovascular outcomes in patients with mild to moderate CKD (K/DOQI stages 2 through 4) and adequately controlled blood pressure, because patients with moderate CKD (stages 3 and 4) were usually excluded from the large cardiovascular outcome trials with statins,44 and/or blood pressure control was not included in the design of those trials.40-42 On the other hand, subgroup analyses of a limited number of lipid trials (Anglo-Scandinavian Cardiac Outcomes Trial45 and the Pravastatin Pooling Project20) do suggest that statin treatment may reduce cardiovascular events in patients with stages 1 through 3 CKD. These data provide an indirect indication of the beneficial effects of lipid lowering in stages 1 to 3 CKD. It is important to realize, however, that patients with stage 4 CKD (eGFR, 15-29 mL/min per 1.73 m2) were absent or the numbers were too small for analysis in these trials. In a recent study, Isbel et al46 showed that, when compared with usual care, a multiple risk factor intervention program in a population of patients with stages 4 and 5 CKD was not associated with reduction in CC-IMT or with improvement in endothelial function. However, only 25% of the patients in Isbel and colleagues' study had stage 4 CKD, and those patients were not analyzed separately.
Therefore, to our knowledge, the ATIC Study is the first randomized, placebo-controlled trial examining the effect of an oxidative stress–lowering strategy in a population of patients with mild to moderate nondiabetic stages 3 and 4 CKD without manifest cardiovascular disease. Also, and in contrast to the above-mentioned studies, 45% (42/93) of our patient population had K/DOQI stage 4 CKD, equally divided between the treatment and the placebo groups (22 patients in the treatment group and 20 patients in the placebo group). Most of the remaining patients (48/93) had K/DOQI stage 3 CKD (25 patients in the treatment group and 23 patients in the placebo group). The treatment strategy had beneficial effects on the CC-IMT and BA-FMD in patients with stages 3 and 4 CKD (data not shown).
The systolic blood pressure did not differ statistically significantly (P = .14) between the 2 groups at any point, and adjustment for systolic, diastolic, or mean blood pressure difference did not alter the CC-IMT, BA-FMD, or urinary albumin excretion results. Therefore, according to our study findings, we conclude that the treatment strategy described herein in conjunction with adequately controlled blood pressure has beneficial effects for patients with stage 3 or 4 CKD who have no prior cardiovascular disease.
A few studies have demonstrated a renoprotective effect of statins.47-49 However, most of these studies were short term, with small patient populations, or subgroup analyses from large statin trials involving subjects at high risk for cardiovascular events but with mild CKD or normal renal function at baseline. After 2 years of treatment in our patient population, we could not demonstrate a statistically significant effect on the eGFR between the groups. Our study was not powered, and the follow-up period may have been too short to demonstrate any effect on the eGFR.
However, we were able to demonstrate a significant attenuation of the increase in urinary albumin excretion over time in the treatment group. Additional analyses suggested that these effects were limited to individuals with urinary albumin excretion of more than 30 mg/24 h, but the hazards of such analyses are well known, and, clearly, this result requires confirmation. Urinary albumin excretion may be a marker of endothelial dysfunction50 and oxLDL is known to down-regulate endothelial nitric oxide activity.51 Therefore, a reduction in oxLDL may have contributed to the improvement in endothelial function, as shown in our population (Figure 3), and thereby to the reduction of urinary albumin excretion.
We studied a selected population of patients with mild to moderate CKD. Our study had limited power and was too short to detect an effect on clinical cardiovascular end points. In other populations, large trials with vitamin E and homocysteine lowering have not shown any beneficial effects on cardiovascular events. However, during the design period of our study, the then-available information suggested that these vitamins could have beneficial effects in patients with renal failure because these patients were known to have increased oxidative stress. Also, small studies with vitamin E in dialysis patients52 at that time showed some promising results. We decided to use the treatment strategies comcomitantly to reduce the number of patients needed to perform this study and to achieve a maximum oxidative stress reduction in the treatment group. Furthermore, we decided to add interventions sequentially and planned to evaluate the effects of individual treatments. We expected (in retrospect, wrongly) the maximum effect of each intervention to be achieved within 6 months after the given intervention and/or that the additional effect of the next step would be clearly distinguishable from the effects of the previous step. Decreases in CC-IMT and improvement in BA-FMD were observed during the whole study period (Figures 2 and 3). In retrospect, we are unable to draw any conclusions on the individual effects of these interventions. Also, the treatment modalities of the present study certainly have effects independent of oxidative stress lowering. We therefore cannot draw any conclusions as to whether the observed improvements were the results of the oxidative stress lowering or of other effects such as reduction of lipid levels.
In conclusion, in nondiabetic patients with mild to moderate CKD with adequately controlled blood pressure and without clinical features of atherosclerosis, a treatment strategy consisting of pravastatin, vitamin E, and homocysteine-lowering therapy resulted in a significant reduction in CC-IMT and a significant improvement in endothelial function and urinary albumin excretion. No significant effect on eGFR was seen. These results suggest, but do not prove, that this treatment strategy might safely reduce the burden of cardiovascular events in this population. Thus, larger studies carried out over a long period with clinical end points will be required to confirm and validate these results.
AUTHOR INFORMATION
Correspondence: Prabath W. B. Nanayakkara, MD, Department of Internal Medicine, VU University Medical Center, PO Box 7057, 1007 MB Amsterdam, the Netherlands (p.nanayakkara{at}vumc.nl).
Accepted for Publication: December 12, 2006.
Author Contributions: Study concept and design: Nanayakkara, van Guldener, ter Wee, and Stehouwer. Acquisition of data: Nanayakkara, Scheffer, Teerlink, and van Dorp. Analysis and interpretation of data: Nanayakkara, van Guldener, ter Wee, Scheffer, van Ittersum, Twisk, Teerlink, van Dorp, and Stehouwer. Drafting of the manuscript: Nanayakkara and Stehouwer. Critical revision of the manuscript for important intellectual content: Nanayakkara, van Guldener, ter Wee, Scheffer, van Ittersum, Twisk, Teerlink, van Dorp, and Stehouwer. Statistical analysis: Nanayakkara, van Ittersum, Twisk, and Stehouwer. Obtained funding: van Guldener, ter Wee, and Stehouwer. Administrative, technical, and material support: Nanayakkara, van Guldener, Scheffer, Teerlink, van Dorp, and Stehouwer. Study supervision: van Guldener, ter Wee, van Ittersum, and Stehouwer.
Financial Disclosure: None reported.
Funding/Support: The Dutch Kidney Foundation (project number C97-1707) and Bristol-Myers Squibb provided the funding for the ATIC Study but had no influence on the data analysis or the manuscript preparation.
Author Affiliations: Departments of Internal Medicine (Dr Nanayakkara), Nephrology (Drs ter Wee and van Ittersum), and Clinical Chemistry (Drs Scheffer and Teerlink) and Institute for Research in Extramural Medicine (Drs Twisk and Stehouwer), VU University Medical Center, Amsterdam, Department of Internal Medicine, Amphia Hospital, Breda (Dr van Guldener), Department of Nephrology, Kennemer Gasthuis, Haarlem (Dr van Dorp), and Department of Internal Medicine, University Hospital Maastricht, Maastricht (Dr Stehouwer), the Netherlands.
REFERENCES
| |
1. Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol. 1998;9(suppl):S16-S23.
FULL TEXT
| PUBMED
2. Baigent C, Burbury K, Wheeler D. Premature cardiovascular disease in chronic renal failure. Lancet. 2000;356:147-152.
FULL TEXT
|
ISI
| PUBMED
3. Henry RM, Kostense PJ, Bos G; et al. Mild renal insufficiency is associated with increased cardiovascular mortality: The Hoorn Study. Kidney Int. 2002;62:1402-1407.
FULL TEXT
|
ISI
| PUBMED
4. Muntner P, He J, Hamm L, Loria C, Whelton PK. Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol. 2002;13:745-753.
FREE FULL TEXT
5. Drey N, Roderick P, Mullee M, Rogerson M. A population-based study of the incidence and outcomes of diagnosed chronic kidney disease. Am J Kidney Dis. 2003;42:677-684.
FULL TEXT
|
ISI
| PUBMED
6. Vanholder R, Massy Z, Argiles A; et al. Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant. 2005;20:1048-1056.
FREE FULL TEXT
7. Cheung AK, Sarnak MJ, Yan G; et al. Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int. 2000;58:353-362.
FULL TEXT
|
ISI
| PUBMED
8. Stenvinkel P, Pecoits-Filho R, Lindholm B. Coronary artery disease in end-stage renal disease: no longer a simple plumbing problem. J Am Soc Nephrol. 2003;14:1927-1939.
FREE FULL TEXT
9. Zoccali C. Cardiovascular risk in uremic patients—is it fully explained by classical risk factors? Nephrol Dial Transplant. 2000;15:454-457.
FREE FULL TEXT
10. Himmelfarb J, Stanvinkel P, Ikizler TA, Hakim RM. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int. 2002;62:1524-1538.
FULL TEXT
|
ISI
| PUBMED
11. Terawaki H, Yoshimura K, Hasegawa T; et al. Oxidative stress in enhanced in correlation with renal dysfunction: examination with the redox state of albumin. Kidney Int. 2004;66:1988-1993.
FULL TEXT
|
ISI
| PUBMED
12. Vaziri ND. Roles of oxidative stress and antioxidant therapy in chronic kidney disease and hypertension. Curr Opin Nephrol Hypertens. 2004;13:93-99.
ISI
| PUBMED
13. Heinecke JW, Rosen H, Suzuki LA, Chait A. The role of sulfur-containing amino acids in superoxide production and modification of low density lipoprotein by arterial smooth muscle cells. J Biol Chem. 1987;262:10098-10103.
FREE FULL TEXT
14. Sakabe K, Fukuda N, Wakayama K, Nada T, Shinohara H, Tamura Y. Lipid-altering changes and pleiotropic effects of atorvastatin in patients with hypercholesterolemia. Am J Cardiol. 2004;94:497-500.
FULL TEXT
|
ISI
| PUBMED
15. Zhang B, Noda K, Matsunaga A, Kumagai K, Saku K. A comparative crossover study of the effects of fluvastatin and pravastatin (FP-COS) on circulating autoantibodies to oxidized LDL in patients with hypercholesterolemia. J Atheroscler Thromb. 2005;12:41-47.
ISI
| PUBMED
16. Ullegaddi R, Powers HJ, Gariballa SE. B-group vitamin supplementation mitigates oxidative damage after acute ischemic stroke. Clin Sci (Lond). 2004;107:477-484.
PUBMED
17. Harris A, Devaraj S, Jialal I. Oxidative stress, alpha-tocopherol therapy, and atherosclerosis. Curr Atheroscler Rep. 2002;4:373-380.
PUBMED
18. Wanner C, Krane V, Marz W; et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353:238-248.
FREE FULL TEXT
19. Wrone EM, Hornberger JM, Zehnder JL, McCann LM, Coplon NS, Fortmann SP. Randomized trial of folic acid for prevention of cardiovascular events in end-stage renal disease. J Am Soc Nephrol. 2004;15:420-426.
|
